DBV DBV Technologies SA

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024

Information regarding the total number of voting rights and

total number of shares of the Company as of May 31, 2024

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
05/31/2024



 		96,493,078



 		 



Total gross of voting rights: 96,493,078



 
 



Total net* of voting rights: 96,236,383



 

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment



EN
04/06/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies présentera des données complémentaires issues de l'ét...

DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et discutera de l'avenir de l'EPIT lors du congrès annuel 2026 de l'AAAAI Châtillon, France, le 10 février (22 :30 CET) 2026 DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et discutera de l'avenir de l'EPIT lors du congrès annuel 2026 de l'AAAAI DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DB...

February 10, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Present Additional Data from the VITESSE Phase 3 S...

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today ...

February 10, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in the Guggenheim Securities Emerging ...

DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tassé’s presentat...

February 9, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participeà la conférence Emerging Outlook: Biotech Su...

DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities Châtillon, France, le 9 février (22 :30 CET) 2026 DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP : 23306J309) (la « Société »), société biopharmaceutique de stade avancé, annonce aujourd’hui la participation de Daniel Tassé, Directeur Général, à une discussion informelle (« fireside chat ») dans le cadre du Guggenheim Securiti...

February 9, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information Regarding the Total Number of Voting Rights and Total Numb...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights01/31/2026 274,852,082  Total gross of voting rights: 274,852,082  Total net* of voting rights: 274,792,237  * Net total = total number of voting rights atta...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch